Piramal Pharma Limited (BOM:543635)

Piramal Pharma Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Operating Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	-3,259	911.3	178.2	-1,865	3,760
Depreciation & Amortization	7,865	7,796	7,170	6,568	5,762
Other Amortization	447.3	367.9	235.5	199	99.7
Loss (Gain) From Sale of Assets	-22.3	-14.4	4.6	4.8	5.4
Asset Writedown & Restructuring Costs	62	501.5	-	-	-
Loss (Gain) From Sale of Investments	-191.6	-90.5	4.8	-25.6	-231.3
Stock-Based Compensation	417.2	480	274.7	-	-
Provision & Write-off of Bad Debts	308.6	269.6	319	420.5	74.4
Other Operating Activities	5,633	3,579	4,202	2,558	1,117
Change in Accounts Receivable	2,172	-2,335	-3,914	892.6	-1,852
Change in Inventory	-7,981	-1,971	-5,318	-1,726	-1,756
Change in Accounts Payable	7,780	182.4	4,043	-2,717	791.2
Change in Other Net Operating Assets	3,294	-753.9	2,845	529.5	-106
Operating Cash Flow	16,526	8,923	10,045	4,839	7,664
Operating Cash Flow Growth	85.21%	-11.17%	107.60%	-36.86%	38.94%

Investing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-8,900	-6,644	-7,120	-9,648	-8,895
Sale of Property, Plant & Equipment	134.4	52.5	16	196.9	324.2
Cash Acquisitions	-	-	-63.3	-733.1	-8,047
Investment in Securities	72.3	1,191	2,586	-3,958	-2,326
Other Investing Activities	433.2	626.1	241.3	754.1	822.7
Investing Cash Flow	-8,260	-4,775	-4,340	-13,388	-18,121

Financing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Short-Term Debt Issued	9,848	8,586	-	18,219	22,536
Long-Term Debt Issued	9,026	2,546	2,401	25,628	-
Total Debt Issued	18,874	11,132	2,401	43,847	22,536
Short-Term Debt Repaid	-	-	-3,504	-14,647	-9,965
Long-Term Debt Repaid	-16,044	-10,922	-8,784	-17,570	-2,684
Total Debt Repaid	-16,044	-10,922	-12,288	-32,218	-12,649
Net Debt Issued (Repaid)	2,830	210.1	-9,886	11,629	9,887
Issuance of Common Stock	28.1	-	10,500	-	-
Common Dividends Paid	-185.5	-144.7	-	-670	-500
Other Financing Activities	-3,062	-4,474	-4,837	-2,781	-1,445
Financing Cash Flow	-389.8	-4,408	-4,224	8,178	7,942

Net Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Foreign Exchange Rate Adjustments	63.5	-108.8	177.9	51.5	-20.4
Miscellaneous Cash Flow Adjustments	0.1	-	-	-	767.4
Net Cash Flow	7,939	-368.7	1,660	-319.5	-1,768

Free Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	7,626	2,279	2,925	-4,809	-1,231
Free Cash Flow Growth	234.58%	-22.08%	-	-	-
Free Cash Flow Margin	8.60%	2.49%	3.58%	-6.79%	-1.83%
Free Cash Flow Per Share	5.75	1.71	2.28	-4.04	-1.04
Levered Free Cash Flow	6,796	-1,437	-1,021	-8,740	-8,823
Unlevered Free Cash Flow	8,911	1,175	1,773	-6,630	-7,643

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash Interest Paid	3,062	4,474	4,696	2,781	1,445
Cash Income Tax Paid	2,102	3,344	-	1,890	1,694
Change in Working Capital	5,266	-4,877	-2,343	-3,021	-2,923

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 2, 2026

Data Sources Report a data error